<DOC>
	<DOCNO>NCT00975988</DOCNO>
	<brief_summary>Non-interventional , open-label , single group , multicentric post-marketing surveillance monitor safety effectiveness TYKERB® tablet administer Korean patient accord prescribe information TYKERB® register trademark GlaxoSmithKline group company .</brief_summary>
	<brief_title>Regulatory TYKERB® Tablets PMS</brief_title>
	<detailed_description>Non-interventional , open-label , single group , multicentric post-marketing surveillance monitor safety effectiveness TYKERB® tablet administer Korean patient accord prescribe information TYKERB® tablet administer capecitabine HER2 overexpressing advanced metastatic breast cancer treatment letrozole treatment postmenopausal woman hormone receptor positive metastatic breast cancer overexpresses HER2 describe prescribe information TYKERB® tablet</detailed_description>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>All subject must satisfy follow criterion PMS entry accord MFDS PMS regulation : Subjects indication locally approve prescribe information Subjects contraindication accord prescribe information</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>PMS ( post-marketing surveillance )</keyword>
	<keyword>TYKERB® tablet</keyword>
</DOC>